Everything automated lives here in full: news headlines, company filings, JONBUR research, Street (broker) reports and big movers.
Posts are people's own views and site summaries of public information. Nothing here is financial advice.
Predicted impact: Low
Routine internal audit cooperation agreement with a housing guarantee body; no material financial effect.
Predicted impact: Low
Q3 operating profit of about 19.2 billion won is small; preliminary earnings were already disclosed.
Predicted impact: Low
Q3 operating profit decline is small against revenue; preliminary earnings already reported in last 14 days.
Predicted impact: Low
Baseball match coverage for KIA Tigers, not company business; no financial impact.
Predicted impact: Low
Same foreign-tourist skin medicine push; the K-Pharmacy recommendation was already reported in the last 14 days.
Predicted impact: Low
Skin medicine marketing to tourists; the K-Pharmacy recommendation was already reported in the last 14 days.
Predicted impact: Medium
Operating profit up 67% year on year, a sizeable change driven by high-value orders.
Predicted impact: Low
Energix ESS cooperation, 2-4.5GWh, already reported in recent items; not a firm order.
Predicted impact: Low
Predicted impact: Low
Wage payout details of already-reported deal; minor for holding company.
Predicted impact: Low
Popular search ranking list; no company-specific news content.
Predicted impact: Low
Q3 cumulative revenue above ₩1T was already covered by preliminary earnings disclosure.
Predicted impact: Low
Predicted impact: Low
KFTC fine over Galaxy S21 disclosure; likely tiny against ₩485T revenue, fine amount not given.
Predicted impact: Low
Wage deal for subsidiary already reported multiple times; limited effect on holding company.
Predicted impact: Low
Q3 profit down 51.3% was previewed in preliminary earnings filing; small versus market value.
Predicted impact: Low
Q3 results already reported; profit decline was flagged in earlier items.
Predicted impact: Low
Index sector reclassification is a label change with no change to the business.
Predicted impact: Low
Volkswagen materials showcase at German exhibition already reported in recent days.
Predicted impact: Low
European ESS push already covered in several recent items; no new deal size.
Predicted impact: Low
Same wage settlement and 55.06% approval vote already reported earlier.
Predicted impact: Low
Subsidiary wage deal already covered repeatedly; minor for the holding company.
Predicted impact: Low
Wage deal already reported in the last 14 days; removes strike risk, small versus ₩21.9T revenue.
Predicted impact: Medium
Atlas robot parts order shared with other suppliers; BHCo's share and size unknown versus ₩1.86T revenue.
Predicted impact: Medium
Possible National Growth Fund stake interest in a ₩377B company; unconfirmed, no size given.
Predicted impact: Low
Routine seasonal appliance promotion; same coupon sale already reported several times recently.
Our model estimate of fair value for Samsung Biologics moved up to a base case of ₩580,299 per share, from ₩472,202 in the previous report. The share price of ₩1,452,000 remains far above even the new bull case, so the change does not alter the gap between the model and the market.
Not financial advice.
Predicted impact: Low
A disclosure the company is required to file. Open the filing for the details. DHX filed this on Oct 27, 2026.
High impactPredicted impact: High
Management-control dispute injunction against board resolution; listing eligibility review also noted, but lawsuit filing already disclosed; lowered one level.
Company filing
Predicted impact: Low
Securities lending balance for Samsung and SK hynix fell ₩11T, 26% in a month; market positioning data.